Title

The Impact of Oxytocin on the Neurobiology of Anorexia Nervosa
Investigating the Impact of Oxytocin on the Neurobiological Underpinnings of Socioemotional Deficits in Anorexia Nervosa
  • Phase

    Early Phase 1
  • Study Type

    Interventional
  • Status

    Completed No Results Posted
  • Study Participants

    16
This study will use a randomized, controlled, double-blind design involving the administration of intranasal oxytocin (INOT) or placebo to adults with anorexia nervosa, restricting subtype and age-matched controls prior to neuroimaging to assess the impact on frontolimbic brain activity in response to socioemotional stimuli as well as eating behavior in a test meal paradigm.
The primary objective of this investigation is to determine the impact of oxytocin (OT), a peptide hormone that influences social affiliation, on socioemotional neural circuitry and eating disorder behavior in anorexia nervosa (AN). Because socioemotional processing deficits appear to play a key role in AN, OT is implicated as a potential biological mechanism by which eating disorder behavior (e.g., restrictive eating) is maintained. Used as a probe, intranasal oxytocin (INOT) provides an innovative method for examining the short-term impact of OT on socioemotional neural processing disturbances and eating disorder behavior in AN. The proposed study tests a theoretical model of the role of OT in the maintenance of AN by using an INOT probe to determine, and potentially alter, neurobiological responses to socioemotional stimuli. Specifically, this study will use a randomized, controlled, double-blind design involving the administration of INOT or placebo to adults with AN restricting subtype and age-matched controls prior to neuroimaging to assess the impact on frontolimbic brain activity in response to socioemotional stimuli. The potential impact of INOT on restrictive eating will also be assessed in a subsequent test meal. We predict that for participants with AN, INOT, but not placebo, will normalize frontolimbic activation in response to social reward stimuli and prefrontal activation in response to social threat stimuli. In addition, the investigators predict that AN participants will display reduced restrictive eating in a test meal paradigm following INOT (but not placebo) administration. Finally, investigators predict that changes in restrictive eating following INOT administration will be mediated by altered frontolimbic responding to socioemotional cues. This investigation will provide an essential link uniting the data supporting the importance of socioemotional processing deficits in AN with the emerging role of INOT in altering the neural circuits involved in social behavior to test an innovative neurobiological maintenance model of AN.
Study Started
Sep 25
2018
Primary Completion
Apr 30
2021
Study Completion
Apr 30
2021
Last Update
Feb 11
2022

Biological Intranasal oxytocin

oxytocin is a peptide hormone that influences social affiliation

Intranasal Oxytocin Placebo Placebo Comparator

Intranasal placebo

Intranasal Oxytocin Experimental

Intranasal oxytocin

Criteria

Inclusion Criteria:

All participants:

Age > 18 years old
Female (given the potential sex differences to endogenous OT to INOT)
Ability to read and speak in English
Right-handed

Anorexia nervosa participants:

DSM-5 diagnosis of AN, restricting subtype (established by the SCID-5-RV),

BMI < 18.5 kg/m2 within the past month

Exclusion Criteria:

All participants

Medical instability or current pregnancy or lactation
Current substance use disorder, psychosis, or bipolar-I disorder
Contraindication for fMRI (e.g., implanted metal)
History of neurological disorder/injury (e.g., stroke; head injury with > 10 minutes loss of consciousness)
Food allergy that cannot be accommodated through substitutions to the laboratory test meal
Lacking capacity to consent
Contraindications for intranasal oxytocin administration
Acute suicidality

Psychoactive medication (e.g., antidepressants, antipsychotics)

Exclusion for participants without anorexia nervosa

Current DSM-5 Axis-I diagnosis or current or past eating disorder diagnosis
BMI < 19.0
No Results Posted